Sanofi (SNYNF) Payables (2009 - 2025)
Sanofi's (SNYNF) quarterly Payables came in at $8.6 billion in Q4 2025, up 6.19% year-on-year from $8.1 billion in Q4 2024, and up 6.99% quarter-over-quarter from $8.0 billion in Q2 2025.
Sanofi (SNYNF) Payables (2009 - 2025) Analysis & Trends
Sanofi has disclosed Payables across 17 years of filings, most recently posting $8.6 billion for Q4 2025.
- Payables for Q4 2025 came in at $8.6 billion, up 6.19% year-over-year; the trailing twelve-month figure through Dec 2025 was $8.6 billion (up 6.19% YoY), and the FY2025 annual result was $8.6 billion, up 6.19% from the prior year.
- Payables came in at $8.6 billion for Q4 2025 at Sanofi, up from $8.0 billion in the prior quarter.
- In the past five years, Payables ranged from a high of $8.6 billion in Q4 2025 to a low of $6.5 billion in Q2 2021.
- The 5-year median for Payables is $7.9 billion (2023), against an average of $7.6 billion.
- Across the five-year window, Payables gained 19.42% in 2021 and slipped 1.68% in 2022, its largest moves.
- Sanofi's Payables stood at $7.1 billion in 2021, then slipped by 1.68% to $7.0 billion in 2022, then gained by 13.43% to $7.9 billion in 2023, then rose by 2.34% to $8.1 billion in 2024, then climbed by 6.19% to $8.6 billion in 2025.
- The last three Payables figures came in at $8.6 billion (Q4 2025), $8.0 billion (Q2 2025), and $8.1 billion (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 96,436,181.12 Bn | 96,436,176.16 Bn | 7.76 Bn | -26.13 Bn |
| 2 | Eli Lilly | 1,017.30 Bn | 1,012.01 Bn | 16.22 Bn | 5.03 Bn |
| 3 | Johnson & Johnson | 579.61 Bn | 557.55 Bn | 15.96 Bn | 27.92 Bn |
| 4 | AbbVie | 402.30 Bn | 392.96 Bn | 10.78 Bn | 33.77 Bn |
| 5 | Merck | 294.24 Bn | 288.59 Bn | 12.09 Bn | 6.01 Bn |
| 6 | Amgen | 191.82 Bn | 179.78 Bn | 5.87 Bn | 2.94 Bn |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn | 645.00 Mn |
| 8 | Pfizer | 149.05 Bn | 136.28 Bn | -1.21 Bn | 4.51 Bn |
| 9 | Bristol Myers Squibb | 116.33 Bn | 105.88 Bn | 8.07 Bn | 4.23 Bn |
| 10 | Sanofi | - | - | 9.49 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 8.57 Bn |
| Jun 30, 2025 | 8.01 Bn |
| Dec 31, 2024 | 8.07 Bn |
| Jun 30, 2024 | 8.00 Bn |
| Dec 31, 2023 | 7.88 Bn |
| Jun 30, 2023 | 8.02 Bn |
| Dec 31, 2022 | 6.95 Bn |
| Jun 30, 2022 | 7.00 Bn |
| Dec 31, 2021 | 7.07 Bn |
| Jun 30, 2021 | 6.47 Bn |
| Dec 31, 2020 | 6.31 Bn |
| Jun 30, 2020 | 5.42 Bn |
| Dec 31, 2019 | 133.27 Mn |
| Jun 30, 2019 | 5.71 Bn |
| Dec 31, 2018 | 5.75 Bn |
| Jun 30, 2018 | 69.22 Mn |
| Mar 31, 2018 | 5.32 Bn |
| Dec 31, 2017 | 5.46 Bn |
| Jun 30, 2017 | 4.73 Bn |
| Dec 31, 2016 | 260.21 Mn |